Codipront 90ml Codeine Syrup Codipront 90ml Codeine Syrup, 2.22 mg/ml + 0.733 mg/ml, syrup 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 935 – 1 205 mg of codeine-poly (styrene, divinylbenzene)-sulfonate, equivalent to 200 mg of codeine. 148.5 – 194 mg of phenyltoloxamine-poly (styrene, divinylbenzene)-sulfonate, equivalent to 66 mg of phenyltoloxamine. Excipient(s) with known effect Each millilitre of syrup contains 2.3 mg of methyl parahydroxybenzoate; Each millilitre of syrup contains 1.0 mg of propyl parahydroxybenzoate; Each millilitre of syrup contains 383.34 mg of sorbitol (as sorbitol 70% solution); Each millilitre of syrup contains 0.87 mg of potassium (as potassium chloride). Each millilitre of syrup contains 0.36 mg of sodium. For the full list of excipients, see section 6.1.
PHARMACEUTICAL FORM Syrup
THERAPEUTIC INDICATIONS Codipront is recommended for the symptomatic relief of acute dry irritating cough in adults and children over 12 years of age.
POSOLOGY AND METHOD OF ADMINISTRATION Posology and duration of treatment depend on the basic disease, as well as on the intensity and frequency of cough. The patient should follow the attending physician instructions. Duration of treatment: The duration of treatment is defined by the doctor
